This month, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), trade groups representing the biopharmaceutical and biotechnology industries, announced that they are challenging Nevada’s Senate Bill (SB) 539 in district court litigation.
This month, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), trade groups representing the biopharmaceutical and biotechnology industries, announced that they are challenging Nevada’s Senate Bill (SB) 539 in district court litigation.
Passed in June 2017 by constitutional majorities in both the Nevada Assembly and Senate, the bill was signed into law by Governor Brian Sandoval (R). Among other provisions, the law requires drug manufacturers to annually disclose list prices set for insulins, profits made, and discounts provided to pharmacy benefit managers (PBMs). It also requires drug makers to explain insulin price increases that are above the prior year’s inflation rate (or twice the inflation rate of the past 2 years).
Manufacturers could face daily fines if they fail to provide the required data. The bill also permits pharmacists to provide patients with information about lower-priced alternative prescription options.
According to the groups’ complaint, the “unprecedented and unconstitutional Nevada law… interferes with the federal patent and trade-secret laws, deprives manufacturers of their property interest in their trade secrets, and improperly overrides the regulatory choices of every other state.” PhRMA and BIO are seeking a declaration from the court that sections of SB 539 are preempted by federal law, and that they violate the US Constitution. They also seek a preliminary and permanent injunction prohibiting implementation or enforcement of the provisions at issue.
“While the purpose of the Act is to control prices for diabetes drugs, neither the Act nor its legislative history explain how transparency will lower prices apart from impermissibly burdening manufacturers’ lawful exercise of federal patent rights. The Constitution entrusts national economic policy to Congress precisely to avoid such outcomes,” according to the group’s complaint.
Governor Sandoval said that the suit did not come as a surprise to his office, and that the state’s attorney general would “vigorously defend this existing state law which was passed with bipartisan majorities of both houses.”
Nevada’s law is not the only state-based drug pricing initiative to find itself the target of a lawsuit this month; trade group the Association for Accessible Medicines has filed a suit in Maryland, claiming that the state’s House Bill (HB) 631 is unconstitutional.
HB 631, originally slated to take effect next month, would require the Maryland Medical Assistance Program to notify the state’s attorney general of increase in the prices of generic or off-patent treatments, and would authorize the attorney general to both demand drug makers’ records and impose penalties on manufacturers who violate the law.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.